Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

6 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Product Highlight - Forxiga

29 Mar 2019
Forxiga provides early cardiorenal benefits beyond HbA1c in a broad type 2 diabetes patient population
• Superior HbA1c reduction vs DPP4i1-2
• Well-established safety profile with no imbalance of AEs* vs placebo3-5
• Early cardiorenal benefits beyond HbA1C in a broad T2DM patients population6

*AEs included are amputations, fractures, bladder cancer or Fournier’s gangrene
Disclaimer: Forxiga is not indicated to reduce the risk of CV events, CV death or hospitalisation for heart failure or for the treatment of CKD

References:
1. Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo- controlled trial. Lancet. 2010;375(9733):2223-2233.                 
2. Rosenstock J, Mathieu C, Chen H, et al. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018;62(4):424-430
3. Data on file. Atlas Approval ID: 801,453.011. AstraZeneca Pharmaceuticals Ltd.
4. FORXIGA Malaysia Prescribing Information (Doc ID-002317198, Version 13.0). April 2018
5. Jabbour S, Seufert J, Scheen A, Karup C, Langkilde AM. The incidence of amputation in the dapagliflozin clinical trial program. Endoc Pract. 2017;23(1):46A.
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapaglifozin and cardiovascular outcomes in type-2 diabetes. N Engl J Med. 2018. doi: 10.1056/NEJMoa1812389

Further information is available in section 11b and in mims.com.
Full prescribing information is available upon request.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

6 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.